Technical Data Sheet

InVivoSIM anti-human IL-17A (Secukinumab Biosimilar)



<u>Attention</u>: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: Lot Specific* Volume: Lot Specific*

Concentration: Lot Specific* (generally 4 to 11 mg/ml) *

Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number: SIM0013
Clone: Secukinumab
Isotype: Human IgG1

Recommended Isotype Control(s): RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme

Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer

Immunogen: Human IL-17A

Reported Applications: in vitro IL-17A neutralization

Functional assays Immunofluorescence Immunohistochemistry Flow Cytometry

ELISA

Formulation: PBS, pH 7.0

Contains no stabilizers or preservatives

Endotoxin: <0.5EU/mg (<0.0005EU/µg)

Determined by LAL gel clotting assay

Purity: >95%

Determined by SDS-PAGE

Sterility: 0.2 µm filtration

Production: Purified from cell culture supernatant in an animal-free facility

Purification: Protein A
Aggregation: <5%

Determined by SEC

RRID: AB_2894734 Molecular Weight:150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Secukinumab making it ideal for research use. This Secukinumab biosimilar reacts with human IL-17A, a 15-20 kDa cytokine expressed by Th17

Bio X Cell, LLC Page 1 of 2

cells, $\gamma\delta$ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells. IL-17A has pleiotropic effects in immunoregulation and inflammation. It plays an important role in anti-microbial and chronic inflammation by inducing cytokine and chemokine production, neutrophil influx, and the production of antibacterial peptides but it is also an inflammatory mediator in the development of autoimmune diseases including rheumatoid arthritis, asthma, multiple sclerosis, and psoriasis. Secukinumab neutralizes IL-17A.

Storage

Store at the stock concentration at 4°C . Do not freeze.

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/fags.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.


Application References

For a complete list of references, visit https://bioxcell.com/sim0013?bxcs=9k1b3a#tab_references or scan the QR code below.



Binding Validation

Validation data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, e-mail technicalservice@bioxcell.com.



Bio X Cell, LLC https://bioxcell.com

+1-866-787-3444

customerservice@bioxcell.com

Conditions: For research use only. Not for human use. Not for use in diagnostic or therapeutic procedures.

Not for resale.

Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC

Bio X Cell, LLC Page 2 of 2